Intuitive Surgical, Inc. ISRG

Intuitive Surgical is expected to announce its third-quarter earnings in October, and Wall Street expects the company’s EPS to increase by a single-digit percentage.

Intuitive Surgical has delivered a 43.1% gain over the past three years, even as the stock has been weaker more recently. This puts fresh focus on whether the current US$412.18 share price is properly backed by the cash the business can generate. With new headlines around robotic surgery and strong recent revenue figures, the key issue now is how that share price lines up against the value implied by its cash flows. The 43.1% return over three years means anyone looking at Intuitive Surgical...

Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.

At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don’t make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a similar reason to pay attention this year, which is that growth […]

Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.

The global medical robots market is projected to grow from USD 20.6 billion in 2026 to USD 41.7 billion by 2031, at a 15.1% CAGR. Growth is driven by demand for minimally invasive surgery, healthcare automation, precision procedures, and advances in AI-powered surgical, rehabilitation, radiosurgery, hospital, and pharmacy robots. Robotic systems will hold the largest market share, while surgical robots will lead by type. Ambulatory surgery centers are set for the fastest end-user growth, and Asi